Petra Acquisition Inc.
REVB
|
$2.1
1.45%
1.43%
39K
|
(0.0% 1d) (-19.6% 1m) (93.5% 1y) (0.0% 2d) (1.0% 3d) (-6.7% 7d) (28.26% volume)
Earnings Calendar:
Market Cap: $ 3,429,164
https://www.revbiosciences.com
Sec Filling | Patents | 2 employees
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
treatment injection diagnostics vaccine rsv respiratory influenza
add to watch list Paper trade email alert is off
Press-releases
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
Published: 2024-03-13 (Crawled : 14:30) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: -4.81%
H: 0.34%
C: -12.46%
presentation care
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
Published: 2024-03-12 (Crawled : 14:30) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: 0.0%
H: 0.0%
C: -7.14%
conference
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
Published: 2024-03-04 (Crawled : 16:00) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: 0.82%
H: 0.0%
C: -7.08%
first study
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
Published: 2024-02-13 (Crawled : 18:00) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: 1.45%
H: 15.36%
C: 7.14%
conference presentation international care
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
Published: 2024-02-01 (Crawled : 12:00) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: -59.77%
H: 2.82%
C: -10.17%
million offering
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
Published: 2024-01-30 (Crawled : 15:00) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: -10.47%
H: 2.98%
C: -31.64%
conference international care
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
Published: 2024-01-23 (Crawled : 15:30) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: 0.26%
H: 7.81%
C: -21.59%
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
Published: 2023-10-04 (Crawled : 14:00) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: 3.89%
H: 0.0%
C: -3.89%
conference
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: 4.44%
H: 0.0%
C: -1.43%
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
Published: 2023-05-22 (Crawled : 20:00) - biospace.com/
REVB | $2.1 1.45% 1.43% 39K
|
|
| O: 6.31%
H: 10.17%
C: 0.85%
financial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10